As of June 4, 2025, Inhibikase Therapeutics Inc (IKT) reports a ROE (Return on Equity) of -29.01%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Inhibikase Therapeutics Inc's ROE (Return on Equity)
Over recent years, Inhibikase Therapeutics Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -29.01% |
| 2023-12-31 | -173.34% |
| 2022-12-31 | -85.79% |
| 2021-12-31 | -38.50% |
| 2020-12-31 | -29.14% |
This gradual decrease highlights how Inhibikase Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Inhibikase Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Inhibikase Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Inhibikase Therapeutics Inc (IKT) | -29.01% |
| Vaccinex Inc (VCNX) | 876.29% |
| Yield10 Bioscience Inc (YTEN) | 582.16% |
| Idera Pharmaceuticals Inc (IDRA) | 333.04% |
| Navidea Biopharmaceuticals Inc (NAVB) | 179.86% |
| StageZero Life Sciences Ltd (SZLS.TO) | 152.27% |
Compared to its competitors, Inhibikase Therapeutics Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.